Top Page
BioNxt Solutions
(OTC:BNXT)
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
BioNxt Solutions Business Overview & Revenue Model
BioNxt Solutions Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.98K | 372.25K | 297.44K | 286.50K | 345.65K |
| Gross Profit | 26.98K | 372.25K | 195.62K | 199.48K | 345.65K |
| EBITDA | -4.32M | -6.48M | -11.51M | -19.19M | -16.05M |
| Net Income | -5.31M | -7.72M | -12.38M | -20.64M | -16.89M |
Balance Sheet | |||||
| Total Assets | 569.36K | 1.27M | 1.61M | 9.73M | 8.28M |
| Cash, Cash Equivalents and Short-Term Investments | 32.35K | 363.65K | 136.20K | 1.35M | 2.58M |
| Total Debt | 4.28M | 4.89M | 4.37M | 5.46M | 3.31M |
| Total Liabilities | 8.43M | 6.55M | 5.74M | 8.06M | 4.28M |
| Stockholders Equity | -7.86M | -5.28M | -4.13M | 1.67M | 4.01M |
Cash Flow | |||||
| Free Cash Flow | -3.03M | -5.37M | -6.23M | -12.61M | -10.36M |
| Operating Cash Flow | -3.03M | -5.17M | -6.23M | -12.16M | -10.20M |
| Investing Cash Flow | 56.21K | 100.84K | -3.86K | -5.31M | -156.47K |
| Financing Cash Flow | 2.64M | 5.29M | 5.02M | 16.23M | 12.65M |
BioNxt Solutions Technical Analysis
BioNxt Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $61.41M | ― | -14.77% | ― | 66.26% | 87.97% | |
68 Neutral | C$90.65M | 21.88 | 5.27% | ― | -1.14% | ― | |
54 Neutral | C$11.58M | ― | -8.79% | ― | -0.29% | -53.83% | |
52 Neutral | $64.33M | ― | 87.69% | ― | -88.95% | 33.33% | |
46 Neutral | C$195.87M | -3.27 | -23.14% | 2.65% | 20.75% | -0.36% | |
46 Neutral | C$8.37M | ― | -50.76% | ― | ― | -4.84% | |
35 Underperform | C$8.81M | ― | -44.58% | ― | -48.33% | 47.56% |
BioNxt Solutions Corporate Events
BioNxt Solutions Inc. announced a non-brokered private placement of convertible debenture units to raise up to $1,200,000. The proceeds will be used for product development, commercialization, intellectual property filings, and general working capital, potentially impacting the company’s growth and market position in the bioscience industry.
BioNxt Solutions Inc. announced the revocation of a management cease trade order by the British Columbia Securities Commission, following the successful filing of its annual financial documents. This development allows the company’s management to resume trading its securities, potentially stabilizing investor confidence and enhancing the company’s market operations.
BioNxt Solutions Inc. has initiated a feasibility study for an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist used in treating type 2 diabetes and obesity. This project aims to leverage BioNxt’s proprietary thin film drug delivery platform to offer a non-invasive alternative to current injectable and tablet-based therapies, potentially improving patient adherence and comfort. The study will assess the compatibility of Semaglutide with the ODF technology and generate data to support future patent filings. This strategic expansion of BioNxt’s platform could significantly impact the rapidly growing GLP-1 therapy market, enhancing the company’s industry positioning and offering new delivery options for stakeholders.
BioNxt Solutions Inc. has announced that its principal regulator, the British Columbia Securities Commission, has granted a management cease trade order (MCTO) due to a delay in filing its annual audited financial statements for 2024. The company is actively working with auditors to meet the June 30, 2025 deadline for filing the required documents, and the MCTO does not affect shareholder trading. BioNxt is committed to maintaining transparency by issuing bi-weekly status reports until the filing is complete.
BioNxt Solutions Inc. has announced that its principal regulator, the British Columbia Securities Commission, has granted a management cease trade order due to the delay in filing its annual audited financial statements for the year ended December 31, 2024. The company is working diligently with its auditors to file the required documents by June 30, 2025, and assures stakeholders that there have been no material changes affecting investors since the default announcement. The MCTO restricts trading by the CEO and CFO but does not affect shareholders’ ability to trade their securities.
BioNxt Solutions Inc. has received formal notice from the European Patent Office of its intention to grant a core patent for the sublingual delivery of anticancer drugs, a significant milestone for the company. This patent will enhance BioNxt’s market position by securing intellectual property rights for its lead product, BNT23001, and other sublingual products targeting autoimmune diseases, paving the way for commercial opportunities and a planned bioequivalence study in Europe.
BioNxt Solutions Inc. has announced a bi-weekly update regarding its management cease trade order (MCTO) issued by the British Columbia Securities Commission. The MCTO restricts the trading activities of the company’s CEO and CFO until the filing of its annual audited financial statements for 2024, expected by June 30, 2025. The company assures stakeholders that it is diligently working with auditors to meet this deadline and that there have been no material changes or additional defaults since the initial announcement. Shareholders’ ability to trade remains unaffected, and BioNxt continues to issue regular updates in compliance with regulatory guidelines.
BioNxt Solutions Inc. has announced the integration of its research, development, and commercialization activities with Gen-Plus GmbH & Co. KG in Munich, Germany, enhancing its R&D capabilities and innovation potential within the European biotech hub. This strategic move aims to leverage Gen-Plus’s advanced infrastructure to develop BioNxt’s lead product, BNT23001, a sublingual thin-film formulation for multiple sclerosis treatment, potentially accelerating its market presence and impact in the pharmaceutical industry.
BioNxt Solutions has announced the acceptance of its first national-level patent filing by the Eurasian Patent Organization, covering sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases. This patent acceptance, which includes BioNxt’s lead product BNT23001 for multiple sclerosis, enhances the company’s commercialization opportunities across Eurasian countries and supports its global patent strategy, potentially strengthening its market position in the treatment of autoimmune diseases.
BioNxt Solutions Inc. announced a delay in filing its 2024 annual financial statements due to delays in receiving necessary financial information. The company has obtained a management cease trade order against its CEO and CFO until the filings are completed, expected by June 28, 2025. The company is committed to adhering to regulatory guidelines and confirms no undisclosed material information.
BioNxt Solutions Inc. is advancing its preparation for a human bioequivalence study for its lead Multiple Sclerosis treatment, BNT23001, a sublingual thin-film formulation of Cladribine. The study, which is expected to last less than 30 days, aims to demonstrate the product’s high absorption rates and bioequivalence compared to existing oral therapies. This development aligns with BioNxt’s mission to improve patient outcomes for chronic diseases, potentially enhancing its industry positioning and offering a novel approach to MS management.